Novo oral Wegovy maintains weight loss post-injection switch, pressures Lilly

Clinical data presented at a medical congress show patients switching from injectable weight-loss drugs to Novo's oral Wegovy sustained weight loss, averaging 4.1% over three months. This bolsters Novo's position in the oral obesity market against Eli Lilly's Zepbound, though long-term efficacy and payer adoption remain uncertain.